Perioperative Pembrolizumab Regimen Receives Positive CHMP Opinion in NSCLC

Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.

Related Keywords

United States ,American , ,American Joint Committee On Cancer Staging Manual ,Clinical Development At Merck Research Laboratories ,European Commission ,European Union ,European Medicines Agency ,Medicinal Products ,Human Use ,Clinical Development ,Merck Research Laboratories ,American Joint Committee ,Cancer Staging ,Accessed February ,Keynote 671 ,Pembrolizumab ,Nsclc ,Non Small Cell Lung Cancer ,Chmp ,Fema ,